Dermata Therapeutics, Inc. (DRMA) Form 424B3 — Oct 21, 2026
Dermata Therapeutics filed a 424B3 prospectus registering the resale of up to 6,919,560 shares of common stock by selling stockholders from its August 2026 private placement. The registered shares equal roughly 140% of the company's ~4.96M shares outstanding as of October 9, 2026, creating a significant potential overhang for the micro-cap stock. The company will receive no proceeds from the resale itself, though it could receive cash from warrant exercises: Series E and F warrants at $1.46 per share (pending stockholder approval under Nasdaq Rule 5635(d)) and pre-funded warrants at $0.001.
Key figures
- Offering Price
- 1.46
- Shares Offered
- 6919560
- Shares Outstanding
- 4955207
- Plain shares
- 933064
- Bank cash fee usd
- 52500
- Bank warrant shares
- 35958
- Warrant exercise price
- 1.46
- Series e warrant shares
- 2294534
- Series f warrant shares
- 2294534
- Last reported sale price
- 1.13
- Pre funded warrant shares
- 1361470
- Bank warrant exercise price
- 1.825
- Insider purchase amount usd
- 2400000
- Private placement close date
- 2026-08-18
- Pre funded warrant exercise price
- 0.001
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.